Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biogen
9
×
life sciences
national blog main
startups
9
×
biotech
boston blog main
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alzheimer's disease
cancer
cancer immunotherapy
deals
clinical trials
fda
novartis
abbvie
eli lilly
gilead sciences
investing
What
bio
roundup
drug
ceo
companies
medicines
new
acquisitions
alzheimer’s
covid
crispr
ipo
price
prices
research
sciences
activity
aims
albert
alliance
announced
annual
approval
approvals
assessed
attention
awards
backed
biggest
biogen
biogen’s
biopharmaceutical
biotech
bourla
bristol
buy
calls
cause
changing
clamped
Language
unset
unknown
Current search:
startups
×
biogen
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Meet the Xconomy Awards San Diego Digital Trailblazer Finalists
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More